|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1001 G STREET NW |
Address2 | SUITE 600 EAST |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 62778-176
|
||||||||
|
6. House ID# 353950008
|
||||||||
| TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Scott Greenberger associate |
Date | 04/17/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008
S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007
S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S 103 Combat Meth Act of 2005
HR 1908 -- and S 1710 -- Patent Reform Act of 2007
HR 3162 -- Children's Health and Medicare Protection Act of 2007
S 1505 -- Affordable Biologics for Consumers Act
S 1695 Biologics Price Competition and Innovation Act of 2007
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeff |
Ricchetti |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis is owned by Novartis AG, Basel, Switzerland
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeff |
Ricchetti |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis is owned by Novartis AG, Basel, Switzerland
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S 2029 Physician Payments Sunshine Act of 2007
HR 6111 Tax Relief and Health Care Act (Medicare)
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization Act
HR 3023 Drug and Medical Device Company Gift Disclosure Act
HR 3963 Children Health Insurance Reauthorization Act of 2007
S 2041 False Claims Act Correction Act of 2007
HR 3610 Food and Drug Import Safety Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeff |
Ricchetti |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis is owned by Novartis AG, Basel, Switzerland
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S 1145 Patent Reform Act of 2007
HR 1908 Patent Reform Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeff |
Ricchetti |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis is owned by Novartis AG, Basel, Switzerland
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |